Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EDGE

Edge Therapeutics (EDGE) Stock Price, News & Analysis

Edge Therapeutics logo

About Edge Therapeutics Stock (NASDAQ:EDGE)

Advanced Chart

Key Stats

Today's Range
$36.57
$36.79
50-Day Range
$0.50
$6.71
52-Week Range
$0.28
$17.38
Volume
3,041 shs
Average Volume
373,201 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Receive EDGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EDGE Stock News Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More Headlines

EDGE Stock Analysis - Frequently Asked Questions

Edge Therapeutics, Inc. (NASDAQ:EDGE) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Bristol-Myers Squibb (BMY), Cerecor (CERC) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/01/2018
Today
5/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EDGE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
38.73

Miscellaneous

Free Float
N/A
Market Cap
$1.16 billion
Optionable
Not Optionable
Beta
3.65
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:EDGE) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners